Bioanalysis – but not as we knew it: an AstraZeneca perspective of the last 10 years evolution to meet a diversifying portfolio

Here we will share an insight to the Translational Biomarker and Bioanalysis group (TBB) analytical strategies used to support AstraZeneca’s new treatment approaches including antisense oligonucleotides (ASOs) and modified messenger RNA (mRNA) therapeutics that modulate protein production in vivo, n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioanalysis 2019-04, Vol.11 (7), p.595-599
Hauptverfasser:	Hawthorne, Glen, Henderson, Neil, Hölttä, Mikko, Stovold, Craig, Wåhlander, Åsa, Wilson, Amanda
Format:	Artikel
Sprache:	eng
Schlagworte:	advanced medicines Antisense oligonucleotides antisense oligonucleotides (ASOs) Chemistry Techniques, Analytical CRISPR CRISPR-Cas9 Drug delivery Enzymes Freezing Gene Editing Immune response Immunoglobulins Inflammation Laboratories messenger RNA (mRNA) mRNA nanomedicine Nanotechnology Oligonucleotides, Antisense - analysis Oligonucleotides, Antisense - genetics outsourcing Peptides portfolio protein Proteins Proteins - analysis Proteins - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!